385 related articles for article (PubMed ID: 31700228)
1. One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.
Zhou Q; Guo C; You A; Wang D; Wang W; Zhang X
Mol Vis; 2019; 25():636-644. PubMed ID: 31700228
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.
Hong IH; Choi W; Han JR
Jpn J Ophthalmol; 2020 Mar; 64(2):196-202. PubMed ID: 31900869
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
4. The role of macular hydration in the evaluation of the effect of intravitreal triamcinolone on visual acuity in eyes with diabetic macular edema.
Sonmez K; Tezel TH; Kaplan HJ
Int Ophthalmol; 2013 Feb; 33(1):15-25. PubMed ID: 22890369
[TBL] [Abstract][Full Text] [Related]
5. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China.
Liu S; Wang D; Chen F; Zhang X
BMC Ophthalmol; 2019 Jul; 19(1):157. PubMed ID: 31337360
[TBL] [Abstract][Full Text] [Related]
6. One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.
Li F; Zhang L; Wang Y; Xu W; Jiao W; Ma A; Zhao B
Curr Eye Res; 2018 Feb; 43(2):218-223. PubMed ID: 29265939
[TBL] [Abstract][Full Text] [Related]
7. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema.
Wei Q; Wan Z; Hu Y; Peng Q
Drug Des Devel Ther; 2019; 13():4367-4374. PubMed ID: 31920286
[TBL] [Abstract][Full Text] [Related]
9. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema.
Jeon SH; Kim M; Roh YJ
BMC Ophthalmol; 2024 Jan; 24(1):25. PubMed ID: 38243166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of postvitrectomy intravitreal triamcinolone therapy for diabetic macular edema.
Costa JF; Sousa K; Marques JP; Marques M; Cachulo ML; Silva R; Gomes N; Figueira J
Eur J Ophthalmol; 2016 Aug; 26(5):485-90. PubMed ID: 26951531
[TBL] [Abstract][Full Text] [Related]
12. Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema.
Kim JH; Kang SW; Ha HS; Kim JR
Korean J Ophthalmol; 2013 Jun; 27(3):186-93. PubMed ID: 23730111
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol.
Hayashi Y; Tatsumi T; Oshitari T; Kaiho T; Takatsuna Y; Arai M; Baba T; Yamamoto S
J Diabetes Res; 2021; 2021():1374891. PubMed ID: 33628832
[TBL] [Abstract][Full Text] [Related]
14. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
[TBL] [Abstract][Full Text] [Related]
15. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
Zhang W; Zhao G; Fan W; Zhao T
BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
[TBL] [Abstract][Full Text] [Related]
16. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
17. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
Tsai MJ; Hsieh YT; Peng YJ
Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.
Liu K; Wang H; He W; Ye J; Song Y; Wang Y; Liu X; Wu Z; Chen S; Fan K; Liu Y; Zhang F; Li Z; Liu L; Zhang J; Zhang X; Ye J; Liang X; Li X; Ke X; Wu Q; Li J; Tao S; Wang X; Rosenfeld P; Heier JS; Kaiser P; Xu X
Br J Ophthalmol; 2022 Oct; 106(10):1436-1443. PubMed ID: 34001667
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
